Serum nesfatin‐1 level in men with diabetes and erectile dysfunction correlates with generalized anxiety disorder‐7: A prospective comparative study

Abstract

Background: Current studies have suggested a close link between nesfatin-1, an appetite-related neuropeptide and gonadal hormones. Objectives:We investigated the association between nesfatin-1 serum level and erectile dysfunction severity in men with diabetes as well as the generalized anxiety disorder-7 questionnaire, the patient health questionnaire-9, serum testosterone, kidney and liver functions, glycated haemoglobin and lipid profile. Materials and methods:Seventy-five participants between 30 and 60 years were enrolled, 25 erectile dysfunction patients with type 2 diabetes (group I), 21 with diabetes and preserved erectile function (group II) and 29 healthy controls (group III).Erectile dysfunction status and severity were determined by the Arabic version of the international index of erectile function-5 for all the participants. Psychological wellbeing was checked by the generalized anxiety disorder-7 questionnaire and the patient health questionnaire-9. Finally, participants were evaluated for serum nesfatin-1, serum testosterone, kidney and liver functions, glycated haemoglobin and lipid profile.Results: Serum nesfatin-1 levels were significantly lower in groups I and II compared to the controls. The international index of erectile function-5 scores had shown significant correlations with serum nesfatin-1, serum testosterone, generalized anxiety disorder-7, patient health questionnaire-9, diastolic blood pressure, glycated haemoglobin, triglycerides, creatinine and albumin/creatinine ratio. Receiver operating characteristic analysis revealed that serum nesfatin-1 ≥ 0.62 ng/ml, serum testosterone ≥2.9 ng/ml, generalized anxiety disorder-7 score ≥7.5, patient health questionnaire-9 score ≥5, glycated hemoglobin ≥6.4%, triglycerides ≥ 144 mg/dl,

Not only a matter of glucose: The andrological consequences of diabetes mellitus

“…For example, Ragab et al demonstrated in a proper-designed clinical trial that nesfatin-1 should be considered a biomarker of ED severity in DM subjects, particularly considering the anxiety typical of ED in DM. 14 However, animal models could provide extremely useful information in the detection of new markers relating DM and ED. Rats models highlighted new molecules, such as Sparc, Lox, Srebf1, 15 and specific genes regulating corpus cavernosum smooth muscle cells development, 16 new biomarkers of ED development in DM.…”

“…For example, Ragab et al. demonstrated in a proper‐designed clinical trial that nesfatin‐1 should be considered a biomarker of ED severity in DM subjects, particularly considering the anxiety typical of ED in DM 14 . However, animal models could provide extremely useful information in the detection of new markers relating DM and ED.…”